Candel Therapeutics (NASDAQ:CADL) Price Target Raised to $25.00 at Canaccord Genuity Group

Candel Therapeutics (NASDAQ:CADL - Free Report) had its price target boosted by Canaccord Genuity Group from $20.00 to $25.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Bank of America initiated coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They issued a "buy" rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Candel Therapeutics in a research report on Wednesday. Finally, Citigroup initiated coverage on shares of Candel Therapeutics in a research report on Thursday, February 20th. They issued a "buy" rating and a $25.00 price target for the company.

Candel Therapeutics Stock Performance

Candel Therapeutics stock traded up $0.38 during trading hours on Wednesday, hitting $8.98. The company had a trading volume of 695,391 shares, compared to its average volume of 1,357,161. The firm has a market cap of $291.63 million, a P/E ratio of -5.19 and a beta of -1.25. Candel Therapeutics has a 1 year low of $1.34 and a 1 year high of $14.60. The company has a 50-day moving average price of $8.35 and a two-hundred day moving average price of $6.76.

Insider Activity at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 13,673 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total transaction of $112,392.06. Following the transaction, the insider now owns 124,207 shares in the company, valued at approximately $1,020,981.54. This represents a 9.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CTO Seshu Tyagarajan sold 14,322 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now owns 96,790 shares in the company, valued at $698,823.80. The trade was a 12.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,529 shares of company stock valued at $313,512 over the last 90 days. Insiders own 41.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC increased its stake in shares of Candel Therapeutics by 9.7% in the fourth quarter. MetLife Investment Management LLC now owns 13,773 shares of the company's stock worth $120,000 after acquiring an additional 1,215 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Candel Therapeutics by 12.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company's stock worth $106,000 after acquiring an additional 1,340 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Candel Therapeutics by 15.2% in the fourth quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company's stock worth $90,000 after acquiring an additional 1,375 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Candel Therapeutics by 75.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company's stock worth $33,000 after acquiring an additional 1,610 shares during the period. Finally, Nuveen Asset Management LLC increased its stake in shares of Candel Therapeutics by 3.0% in the fourth quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company's stock worth $592,000 after acquiring an additional 2,009 shares during the period. Institutional investors and hedge funds own 13.93% of the company's stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.